DE-LYCRA/DCC
9.5.2024 03:01:32 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative, sustainable solutions for the apparel and personal care industries, announced today that it has signed a letter of intent with Dairen Chemical Corporation (DCC) to convert QIRA®—the next generation of 1,4 butanediol (BDO)—into low-impact PTMEG, the main ingredient in patented bio-derived LYCRA® fiber. Dairen will be the first company in the world to mass produce this low-impact bio-PTMEG at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509462079/en/
Left to Right: Steve Stewart, chief brand and innovation officer, The LYCRA Company, and Shean-Tung Lin, Chairman, Dairen Chemical Corporation (DCC), sign a letter of intent for DCC to convert QIRA® into low-impact PTMEG for bio-derived LYCRA® fiber. (Photo: Business Wire)
In September 2022, The LYCRA Company and Qore® announced they were joining forces to enable the production of bio-derived LYCRA® fiber made with QIRA®. Now, DCC joins this distinctive collaboration, converting QIRA® into bio-PTMEG. This unique PTMEG will make up the renewable portion of LYCRA® fiber, accounting for 70% of the fiber’s content. It is being made exclusively for The LYCRA Company to its stringent specifications. With its low-impact allyl alcohol process, DCC has pioneered a technology that creates the lowest-impact PTMEG available, which is cleaner and has a lower carbon footprint than product produced with natural gas or coal.1
The LYCRA Company, Qore®, and DCC are united by a shared commitment to R&D, health and safety, sustainability, and conservation. To mark this event, Steve Stewart, The LYCRA Company’s chief brand and innovation officer, presented DCC with a Green Partner Award. The award acknowledges DCC’s ongoing sustainability efforts and commitment to creating low-impact products.
“Our collaboration heralds a brand-new era of environmentally conscious production activities, fueled by our shared commitment to reducing carbon footprints and developing world-leading eco-friendly solutions,” said DCC’s chairman, Lin Shean-Tung. “Sustainability is not merely a trend, but an imperative for the future of our planet. We are honored to receive the Green Partner Award and embark on this journey alongside The LYCRA Company, advancing sustainable practices in the industry.”
Available in early 2025, patented bio-derived LYCRA® fiber made with QIRA® will be the world’s first renewable spandex available on a large scale. By using annually renewable dent corn, an initial screening calculation indicates that the carbon footprint of LYCRA® fiber potentially could be reduced by up to 44 percent2 compared to LYCRA® fiber without bio-derived materials. Further, the fiber will offer equivalent performance to traditional LYCRA® fiber, making it an easy replacement for mills, brands and retailers.
“We are excited to collaborate with DCC to bring bio-derived LYCRA® fiber made with QIRA® to market and realize our shared vision for a more sustainable value chain,” said Stewart. “Given the combination of using bio-derived input from corn, plus conversion at a state-of-the-art QORE® facility run on wind power, and transformation to PTMEG using DCC’s low-impact process, we anticipate the potential for additional reductions as we go into production.”
For many years, Dairen has demonstrated its sustainability efforts in raw materials management, waste elimination, process enhancement, innovations, and more. It has also achieved significantly lower carbon emissions in its product offerings than its competition.
“Sustainability has evolved from fulfilling requirements to being a competitive advantage,” said Simon Chuang, vice president of global sourcing and procurement at The LYCRA Company. “We’re committed to selecting, promoting, and expanding our business with supply partners like DCC who embrace and drive meaningful sustainability efforts.”
Visit lycra.com/qira to learn more about bio-derived LYCRA® fiber made with QIRA®.
1Estimate from Cradle-to-Gate Screening PCF for a representative DAIREN PTMEG manufacturing facility, year 2023, prepared by DNV Business Assurance Co., Ltd.
2Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. Qore® and QIRA® are trademarks of Qore® LLC. For more information and inquiries visit https://www.myqira.com/.
About Dairen Chemical Corporation (DCC)
Founded in 1979, DCC is a leading maker of acetyl and allyl chemicals. The company board has been chaired by Mr. Lin Shean-Tung since June 2019. DCC operates seven production sites in Asia and serves customers in more than one hundred countries. Major products include Vinyl Acetate Monomer, Vinyl Acetate Ethylene (VAE) Emulsion, VAE Redispersible Powder, Allyl Alcohol, 1,4-Butanediol and PTMEG. Headquartered in Taipei, Taiwan, its productions sites are in Taiwan, China, Singapore and Malaysia. Under the leadership of Chairman Lin, DCC is expanding its international activities and enhancing its global presence.
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509462079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 09:01:00 CEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 09:00:00 CEST | Press release
IQM Radiance systems now operate as computational nodes inside HPC environments. The hybrid workflows are scheduled and managed alongside CPUs and GPUs by the same workload manager already operational in the world’s top supercomputing centers. The new HPC Integration Service reflects the company’s production quantum model – end-users own the hardware, run it on their infrastructure, and operate it under their control. IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across ente
Visa Flexible Credential Brings More Flexible Ways to Pay to Zilch Cardholders in the UK12.5.2026 09:00:00 CEST | Press release
Visa, Zilch and Thredd collaborate to help issuers deliver a simpler, more flexible card experience for users. Visa, a world leader in digital payments, Zilch and Thredd today announced the introduction of Visa Flexible Credential (VFC) on Zilch cards in the UK, enabling more flexible ways to pay through a single, familiar card experience. Demand for flexible payment experiences continues to grow. Many people no longer think in fixed terms such as debit or credit, instead wanting the ability to choose what works best for a specific purchase in the moment. In the UK, 87% of people surveyed say flexible payment options support their financial or lifestyle goals1. Visa Flexible Credential is designed to support this shift, helping issuers offer more choice through one familiar card that already works at more than 150 million merchant locations worldwide. The new capability allows different payment options to sit behind one card or digital credential, giving cardholders greater choice and
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 08:43:00 CEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom